Company intelligence / Profile preview

Cognition Discovery Foundation

Purchase, New York, United States

Ownership: Private
Development stage: Other

Overview

Cognition Discovery Foundation is a research-oriented organization closely associated with the development of novel therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The foundation supports the advancement of small molecule candidates designed to displace toxic amyloid beta oligomers from neuronal receptors. Its primary focus involves the sigma-2 receptor complex as a therapeutic target to restore synaptic function and slow cognitive decline. By bridging the gap between academic discovery and clinical application, the foundation plays a key role in the neurobiology research ecosystem.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

Cognition Therapeutics

Beyond the preview

Go deeper on Cognition Discovery Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cognition Discovery Foundation.

Explore the full profile